Skip to main
ESLA
ESLA logo

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc. is making significant strides in its clinical development of CD19 and CD22-targeted ARTEMIS T-cell therapies, with promising results from the EB103 program indicating a favorable safety profile and successful patient outcomes. The company's advancement into higher dose cohorts enhances its competitive positioning in the evolving T-cell therapy landscape, potentially addressing unmet treatment needs in B-cell malignancies and autoimmune conditions. Additionally, Estrella's innovative Artemis Technology platform may unlock new market opportunities in immunology and solid tumors, reinforcing the company's future growth potential.

Bears say

Estrella Immunopharma Inc's financial outlook appears concerning due to the lack of comprehensive data outlining projected revenue streams or market demand for its CD19 and CD22-targeted therapies in the competitive landscape of blood cancers and solid tumors. The repeated financial figures related to China’s relapsed/refractory B-cell Non-Hodgkin’s lymphomas indicate potential market size but fail to provide substantive context on the company's anticipated share or its ability to penetrate this market successfully. Moreover, without clear profitability metrics or clinical trial results, the investment risks remain elevated, which could deter potential investors and impact stock performance negatively.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.